A splicing variant of rat striatin-3 (rSTRN3g) was found to associate with estrogen receptor-a (ERa) in a ligand-dependent manner. In two-hybrid and pull-down analyses, estradiol induced an interaction between rSTRN3g and ERa. STRN3g protein was found in nuclear extracts from rat uterus and human cell lines. Overexpression of rSTRN3g induced a decrease in ERa transcriptional activity but had no effect on ERb activity. Immunoprecipitation analyses showed that rSTRN3g interacts with both the ERa and the catalytic subunit of protein phosphatase 2A (PP2A(C)). The transrepressor action of rSTRN3g was overcome by okadaic acid, an inhibitor of PP2A(C), and by cotransfection of PP2A(C) siRNA. rSTRN3g caused dephosphorylation of ERa at serine 118 and this was abrogated by okadaic acid. ERa lacking phosphorylation sites at either serine 118 or 167 was insensitive to the corepressor action of rSTRN3g. These observations suggest that an rSTRN3g-PP2A(C) complex is recruited to agonist-activated ERa, thereby leading to its dephosphorylation and inhibiting transcription.
Introduction
Estrogen receptors (ERa and ERb) are the ligandactivated, phosphorylated transcription factors (McKenna & O'Malley 2002 , Edwards 2005 . Like other nuclear receptors, ERa exerts its transactivational function through interaction with coregulatory proteins, coactivators and corepressors. Recent advances with cDNA microarrays have allowed an appreciation of the magnitude of the genomic response to 17b-estradiol (E 2 ). In the estrogen-responsive breast cancer cells, MCF-7, 438 out of the 12 000 genes examined were regulated by E 2 ; 70% of these 438 genes were down-regulated (Frasor et al. 2003) . About one-third of the genes that were up-regulated by E 2 responded transiently, i.e., their mRNA levels increased dramatically within the first few hours following the addition of E 2 but then decreased to near pre-stimulation levels over the course of the next few hours, even though E 2 remained in the culture medium (Frasor et al. 2003) . This type of transient transactivational response was observed previously for the early response genes, c-fos, c-myc, and c-jun (Loose-Mitchell et al. 1988 , Weisz & Bresciani 1988 , Bigsby & Li 1994 . On the other hand, the E 2 -induced increase in mRNA levels for pS2 (Brown et al. 1984 , Cavailles, et al. 1989 , Metivier et al. 2003 , cathepsin D (Cavailles et al. 1989) , and growth factors, amphiregulin and SDF-1 (Frasor et al. 2003) , occurs early after stimulation and is maintained through at least 24 h. It is not known how some genes are down-regulated by estrogen while others are up-regulated. Furthermore, the mechanisms responsible for quickly shutting down E 2 -induced transactivation of some genes, but not others, are unknown.
Transactivational effects of ERa are regulated via proteins that become associated with the receptor. Upon activation with ligand and/or phosphorylation via growth factor signaling pathways, ERa binds to estrogen response elements or to other transcription factors, thereby tethering it to the promoter region in target DNA; simultaneously, there is a conformational change in ERa, permitting it to interact with a wide array of nuclear receptor coregulatory proteins (McKenna & O'Malley 2002 , Smith & O'Malley 2004 , Edwards 2005 . Coactivator proteins have intrinsic enzymatic activity or they recruit other proteins with enzymatic action that modifies histones, thereby changing the chromatin structure and allowing the formation of a complex of proteins, which directly or indirectly interacts with the pre-initiation complex (McKenna & O'Malley 2002 , White et al. 2004 ). One of the major coactivator proteins, steroid receptor coactivator-3 (SRC-3), is active only if it is in its fully phosphorylated state (Wu et al. 2004) . Corepressor proteins, such as silencing mediator of the retinoid and thyroid hormone receptor (SMRT) and nuclear receptor corepressor (NCoR), negatively regulate ERa activity when an antagonist occupies the receptor's ligand pocket; SMRT and NCoR bring proteins with histone deacetlyase (HDAC) activity into the complex, thereby shutting down transactivation (Smith & O'Malley 2004 , White et al. 2004 . Negative regulation in the presence of agonist is achieved through recruitment of corepressors, LCoR, RIP140, and HDAC proteins (Metivier et al. 2003 , White et al. 2004 ). In addition, ERa protein levels are down-regulated by E 2 -induced interactions between the receptor and the members of the proteosomal pathway (Fan et al. 2002 (Fan et al. , 2003 . Elegant experiments using immunoprecipitation (IP) and chromatin immunoprecipitation techniques have shown that the recruitment of regulatory proteins occurs in an ordered and cyclical fashion (Shang, et al. 2000 , Metivier et al. 2003 .
In a recent report, striatin (STRN) was described as an ERa-interacting protein (Lu et al. 2004) . STRN is a member of a family of multimodal proteins that include striatin-3 (STRN3) and striatin-4 (STRN4). Striatins have several putative functional domains, such as caveolin-and calmodulin-binding domains and protein-interacting motifs (Muro et al. 1995 , Castets et al. 1996 , Castets et al. 2000 , Moreno et al. 2000 . Shang et al. (2000) and Lu et al. (2003) found that the ERa-STRN interaction plays a role in the non-genomic effects of estrogen in endothelial cells (Lu et al. 2004) . Herein, we describe the agonist-induced interaction between the ERa and an isoform of STRN3, rSTRN3g, isolated from the rat uterus. Evidence is presented indicating that rSTRN3g represses ERa transactivational activity through a novel mechanism involving a protein phosphatase (PP2A).
Materials and methods

Chemicals and cells
Treatment chemicals, E 2 , 4-hydroxytamoxifen (Tam), and okadaic acid (OA), were purchased from Sigma Corp. Human breast cancer cell lines, MDA-MB-231 and MCF-7; the human cervical carcinoma cell line, HeLa; the human ovarian cancer cell line, BG-1; and immortalized monkey kidney cells, Cos-1, were purchased from ATCC (Manassas, VA, USA). The cell lines were maintained in DMEM supplemented with 10% FBS. Experimental stimulation with hormone was performed in media free of phenol red and supplemented with 3% charcoalstripped serum (HyClone Laboratories Inc., Logan, UT, USA).
Plasmids rSTRN3g cDNA was cloned into the expression vectors, pcDNA3 and pcDNA3-His/myc tag, purchased from Invitrogen. The estrogen-responsive luciferase reporter gene, 2XERE-pS2-luc, was reported earlier (Long et al. 2001) ; briefly, it was generated by ligating two consensus ERE sites into the minimal promoter region of the pS2 gene and ligating this into the pGL3 luciferase (firefly) reporter plasmid (Promega, Madison, WI, USA). The ERa expression vector (HEGO) was obtained from Dr P Chambon (Institut de Génétique et de Biologie Moléculaire et Cellulaire, Strasbourg, France). Phospho--mutants of ERa were the generous gift of Dr Simala Ali (Imperial College, London) and are described earlier (Ali et al. 1993 , Campbell et al. 2001 . Control reporter plasmids, pCMV-b-galactosidase (pCMV-b-gal) and pRL-tk-renilla-luciferase (pRL-TK), were purchased from Promega.
Yeast two-hybrid reporter assays
The yeast two-hybrid screening was performed as described previously (Fan et al. 2002) . Briefly, a triple selection system was used. The yeast strain J69-4A was cotransformed with the GAL4 DNA-binding domain plasmid containing the ERa hybrid, pBD-GAL4-ERaAF2 (amino acid residues 290-600 of rat ERa) and the rat uterine cDNA library cloned into the GAL4 activation domain plasmid, pAD-Gal4. Yeast transformants were plated onto synthetic minimal medium agar lacking leucine, tryptophan, histidine, and adenine for 6 days at 30 8C. ERa-interacting clones were identified by their ability to grow in the selective plates and to activate LacZ reporter gene as indicated by blue colonies when X-Gal (Boehringer Mannheim, Indianapolis, IN, USA) was added to the culture. To further investigate the liganddependent and -independent interactions between rSTRN3g with the AF2 domain of ER, we used the yeast two-hybrid system in solution culture, also as described previously (Fan et al. 2002) . Yeast transformed with pBD-GAL4-ERaAF2 and pAD-GAL4-rSTRN3g was grown in liquid culture containing 10 K8 M E 2 , 10 K6 M Tam, or vehicle. The b-gal expression levels were determined using a chemiluminescent reporter assay (PE Applied Biosystems, Foster City, CA, USA).
GST pull-down assay
Glutathione S-transferase (GST) fusion pull-down experiments were performed as described previously (Fan et al. 2002) .
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S-labeled full-length ERa or -b was incubated with GST-rSTRN3g bound to glutathione-Sepharose beads in the absence or presence of 10 K8 M E 2 . After washing four times, specific interacting protein was eluted and analyzed by SDS-PAGE and autoradiography.
Transient transfection reporter assays
HeLa, MDA-MB-231, and BG-1 cells were maintained in DMEM with 5% FBS. Two days before transfection, the B TAN and others . Striatin-3g represses estrogen action cells were seeded onto 12-well dishes (10 5 cells/well) in phenol red-free DMEM containing 3% dextran-coated charcoal-stripped serum. The cells were transfected with equal amounts of total plasmid DNA (adjusted by adding corresponding empty vectors) using Tfx-20 reagent (Promega) according to the manufacturer's guidelines. After 1 h, transfection medium was replaced with phenol red-free medium containing 3% stripped serum and appropriate treatments (vehicle, hormone, or okadaic acid plus hormone). Cell lysates were prepared 20 h after treatment using reporter lysis buffer (Promega). All cells were cotransfected with a non-inducible reporter, either pCMV-b-gal or pRL-TK. Luciferase activities (firefly and renilla) were determined using the Promega Luciferase Assay System; b-galactosidase was assayed with a luminescence reagent kit (Tropix, Foster City, CA, USA). The level of firefly luciferase (2XERE-luc) was expressed as relative light units, normalizing against b-gal or renilla luciferase activity to correct for transfection efficiency. All experiments were performed in quadruplicate and repeated at least two times.
PP2A(C) siRNA
HeLa cells were seeded onto a 24-well dish. Using the same reagents as described above for reporter assays, the cells were transfected with ERa, 2XERE-luc, pCMVb-gal, and STRN3g or its empty vector, and with siRNA for PP2A(C) (Dharmacon, Lafayette, CO, USA; 100 pmol/well) or with a non-target siRNA supplied by the manufacturer. The following day the cells were treated with vehicle or 10 K8 M E 2 and then lysed 18 h later. Luciferase activity in the lysate was normalized against b-galactosidase activity. In separate culture dishes, HeLa cells were similarly transfected with or without the addition of PP2A(C) siRNA and lysed 24 h later. Immunoblot analysis of PP2A(C) and STRN3g in the lysate was performed and the density of the PP2A(C) bands was measured.
Western blot and immunoprecipitation
Whole cell lysates, cytoplasmic extracts, and nuclear extracts were prepared using the reagents and the procedures provided in a Nuclear Extract Kit (Active Motif, Carlsbad, CA, USA). Briefly, cells were seeded onto 100 mm dishes in complete culture media (with phenol red) containing 10% FBS and grown to approximately 75% confluence. The cells were washed with PBS and collected by scraping in a buffer containing protease and phosphatase inhibitors. The cells were either lysed in complete lysis buffer to produce whole cell lysate or treated sequentially with kit components according to the manufacturer's instructions to produce cytoplasmic and nuclear extracts. Endometrial scrapings from ovary-intact or ovariectomized rats (done using an IACUC-approved protocol) were lysed in the buffer containing protease inhibitors (20 mM Tris, pH 7 . 5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 2 . 5 mM sodium pyrophosphate, 1 mM b-glycerol phosphate, 1 mM Na 3 VO 4 , 1 mg/ml leupeptin, 1 mM phenylmethylsulphonyl fluoride, PMSF).
Proteins were resolved by SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted. Antibodies used included: anti-phospho-S118-ERa (Cell Signaling, Beverly, MA, USA), anti-ERa (HC20, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-SG2NA (S-68, Upstate Biotechnologies, Lake Placid, NY, USA), and anti-PP2A(C) (C-20, Santa Cruz Biotechnology). Horseradish peroxidase-conjugated secondary antibodies (Cell Signaling) were applied and immunoblotted proteins were visualized using Lumiglo reagent (Cell Signaling).
Cos-1 cells were cotransfected with HEGO and a vector that expresses His-tagged rSTRN3g. The following day the cells were used in an immunoprecipitation assay to determine whether rSTRN3g interacts with PP2A and ERa. For immunoprecipitation, 10 ml anti-His-tag polyclonal antibody (Cell Signaling) were added to 200 ml cell lysate and incubated overnight at 4 8C. A slurry of Sepharose protein A plus protein G was added, and the mixture was shaken for 4 h at 4 8C. After washing four times with cell lysis buffer, the proteins were extracted from the beads in SDS-sample buffer and applied to 10% SDS-PAGE. Immunoblot analysis was performed as described above.
Statistical analyses
Assays were done in quadruplicate. All error bars represent standard deviation from the mean. ANOVA was applied to data, followed by Bonferroni's tests to determine differences between individual means.
Results rSTRN3g associates with ERa
Using the carboxy portion of ERa as bait in a yeast twohybrid system, we identified a rat protein that associates with ERa in a ligand-dependent manner. Sequence analysis of the cDNA retrieved from the yeast clone revealed that this protein was a member of the striatin family of proteins that include striatin (STRN, calmodulin-binding protein), striatin-3 (STRN3, SG2NA, calmodulin-binding protein-3), and striatin-4 (STRN4, zinedin, calmodulin-binding protein-4) (Castets et al. 1996 , Bartoli, et al. 1998 . The particular form of striatin that we found is a hitherto unreported splice variant of striatin-3 that we refer to as rSTRN3g (GenBank DQ473607). The rat STRN3 gene (GenBank gene ID 114520) is composed of 22 putative exons, out of which 18 code for amino acid sequence. The structure of the 18 coding exons for rat, mouse (GenBank gene ID 94186), and human STRN3 (GenBank gene ID 29966) are similar, and, as shown in Fig. 1 , they produce nearly identical proteins. Two splicing isoforms of the human gene have been identified, hSTRN3a and -b (as designated in SwissProt, ID Q13033; http://us.expasy.org/uniprot/ Q13033); the a-isoform (713 aa) is produced when exons 8 and 9 are omitted from the transcript; the fulllength protein (797 aa) is referred to as the b-isoform.
The rat g-isoform that we have identified also omits the two middle exons, identified as exons 12 and 13 in the rat genomic sequence. In addition, the rSTRN3g transcript represents a read-through of the intron that follows exon 15, adding three amino acid codons and a STOP codon to the in-frame sequence. Furthermore, the in-frame STOP codon is conserved between the rat and human exon/intron sequences, suggesting that the truncated version may exist and has a functional role in humans as well. In the cloned cDNA for rSTRN3g, the sequence that follows this STOP codon is identical to the ensuing intron, exons 16 and 17, plus approximately 1 kb of intronic sequence that follows exon 17. Several putative functional domains have been B TAN and others . Striatin-3g represses estrogen action identified in STRN3 proteins, including caveolin-and calmodulin-binding domains, transactivation and transrepression domains, and six WD40 repeat domains believed to function in protein-protein interactions. Thus, the protein sequence of rSTRN3g is similar to hSTRN3a but is truncated in the carboxy end, having only one out of the six WD40 repeat motifs found in other striatin proteins.
Two-hybrid analysis shows that interaction between ERa and rSTRN3g is dependent upon agonist stimulation; protein-protein interaction was induced by estradiol but not by the receptor antagonist, 4-hydroxytamoxifen (Fig. 2) . In an in vitro, GST pulldown assay, estradiol induced the interaction between rSTRN3g and ERa, but not with ERb (Fig. 3) .
The truncated nature of rSTRN3g was confirmed through immunoblot analysis of the protein produced by expression vectors transfected into mammalian cells. The full-length cDNA was cloned into an expression vector and when transfected into Cos-1 cells (Fig. 4) or HeLa cells (not shown), it produces a protein of approximately 50 kDa that is detectable with an antibody, S-68, directed against a peptide common to the N-terminal amino acid sequence of striatin and STRN3 in both humans and rats. The S-68 antibody also detects endogenous STRN3a (94 kDa), -b (102 kDa), and -g in the lysates of cell lines and homogenates from rat uterus (Fig. 4) . Cos-1 cells expressed STRN3a but not STRN3b. Proteins from human cell lines were derived from either whole cell lysates or extracts made from the cytosolic or nuclear fractions. Human cell lines expressed the three STRN3 isoforms variably. HeLa and MCF-7 cells expressed all three proteins; STRN3b was found in both cytoplasmic and nuclear extracts while STRN3a and -g were found only in the nuclear extracts. BG-1 cells did not express STRN3a and only a very small amount of STRN3g could be detected in the nuclear extract. The rat uterus of ovaryintact animals expressed the a, b, and g STRN3 isoforms, and after ovariectomy they also expressed an additional antibody-interacting protein of approximately 62 kDa; this latter observation was made in three separate sets of uterine homogenates. Whether the 62 kDa band represents yet another isoform of STRN3 remains to be determined. In the original report on the characteristics of cloned SG2NA (STRN3b), Muro et al. (1995) found that the expressed cDNA produced three bands; it was suggested that the two lower bands that were in the range of 60-66 kDa were the result of proteolytic degradation. Perhaps the intermediate band found in homogenates of ovariectomized rat uterus is also a product of proteolysis.
rSTRN3g represses activity of ERa
In mammalian cells, including human breast cancer cells, MDA-MB-231; human cervical cancer cells, HeLa (Fig. 5) ; or monkey kidney cells, Cos-1 (not shown) rSTRN3g blocks ERa transcriptional activity in a dosedependent manner without altering basal levels of the reporter gene. While rSTRN3g is effective against ERa, it has no effect on transactivation by ERb (Fig. 5b) . The dose of STRN3g required for inhibition of E 2 -induced ERa activity is not affected by cotransfection of SRC-3 (Fig. 5c ), indicating that the inhibitory effect is not a matter of competition for coactivator binding to receptor.
rSTRN3g acts through protein phosphatase PP2A
The corepressor action of rSTRN3g may be related to protein dephosphorylation. Others had reported that the STRN3 behaves as a B-subunit of the PP2A (Moreno et al. 2000) . PP2A acts on phosphorylated proteins only as a trimeric complex including the catalytic subunit (PP2A(C)), a stabilizing subunit (PP2A(A)), and the substrate-recognizing subunit (PP2A(B)) (DepaoliRoach et al. 1994 , Csortos et al. 1996 , Janssens & Goris 2001 . We tested whether the corepressor action of rSTRN3g was related to its function as a PP2A(B) subunit. Accordingly, the cells were pretreated with 10 K7 M okadaic acid, the inhibitor of PP2A, prior to stimulation with estrogen in the presence or absence of the vector expressing rSTRN3g; pretreatment allows okadaic acid to enter the cells in sufficient quantity to reduce PP2A(C) activity by 50% at the time of adding E 2 (Favre, et al. 1997) . The ERa-positive human ovarian cancer cell line, BG-1 was used in this analysis because, unlike the breast cancer cell lines, it was found to be tolerant of okadaic acid treatment. Okadaic acid slightly enhanced ERa action and it blocked the repressive effect of rSTRN3g (Fig. 6a) .
Since okadaic acid can inhibit other protein phosphatases, we used an siRNA technique to determine the effect of specifically knocking down PP2A(C) (Fig. 6b-d) . HeLa cells were transfected with expression vectors for ERa and rSTRN3g and the estrogen-responsive reporter, with or without the addition of siRNA for PP2A(C). The cells were left untreated for 24 h to allow clearance of endogenous PP2A(C) and then they were treated with vehicle or E 2 for 18 h. E 2 -induced enhancement of luciferase expression was inhibited by rSTRN3g and this effect was blocked by the addition of PP2A(C) siRNA. The addition of non-target siRNA had no effect on the repressive effect of rSTRN3g. In separate cultures, HeLa cells were similarly transfected with or without the addition of PP2A(C) siRNA and lysed 24 h later. Immunoblot analysis of total cellular lysate showed that siRNA treatment reduced PP2A(C) protein levels by an average of 52%. Since transfection efficiency in HeLa cells is never better than approximately 50% under the conditions employed in the siRNA experiment (data not shown), it is likely that there is very little, if any, PP2A(C) protein in the transfected cells.
The above results suggest that rSTRN3g, acting as a B-subunit of PP2A, directs dephosphorylation of ERa or the proteins associated with ERa at the promoter, thereby turning off the transactivation of the estrogenresponsive gene. Using immunoprecipitation of the His-tagged rSTRN3g, we demonstrated that rSTRN3g, ERa, and PP2A(C) form a complex in the cell and estrogen activation of ERa enhances the formation of this complex (Fig. 7) . If the corepressor action of rSTRN3g derives from its ability to bring PP2A(C) into the complex of proteins formed through interactions with ERa at the promoter, then we would expect it to cause dephosphorylation of ERa and/or those proteins in the complex. To test this we examined the phosphorylation state of ERa, with and without the addition of rSTRN3g (Fig. 8) . In the absence of rSTRN3g, estrogen induced a dramatic increase in the amount of ERa that was phosphorylated at serine 118; the addition of rSTRN3g abrogated this effect. Furthermore, the effect of rSTRN3g on ERa phosphorylation was blocked by okadaic acid. Thus, the presence of rSTRN3g caused an okadaic acid-dependent dephosphorylation of ERa in at least one known phosphorylation site and this action correlates to inhibition of ERa transactivational activity. Using ERa phosphorylation mutants, we found that one other phosphorylation site, serine 167 is also critical to the inhibitory action of rSTRN3g. When either serine 118 or serine 167 of ERa was mutated to alanine, the inhibitory action of rSTRN3g was abrogated (Fig. 9) . The suppressor action of rSTRN3g was unaffected by Figure 4 STRN3 isoforms expressed in rat uterus and human cell lines. Proteins from tissue homogenates of rat uterus or lysates of cell lines were separated by SDS-PAGE and analyzed by immunoblot using the S-68 SG2NA antibody. Cos-1 cells (Cos) were transfected with empty vector (K) or the expression vector for STRN3g (C). Proteins from human cell lines were derived from whole cell lysates (W), cytoplasmic extracts (C), or nuclear extracts (n). Uteri were derived from either ovaryintact (int) or ovariectomized (ovx) rats and endometrial scrapings were homogenized in lysis buffer.
mutation of serines to alanines at positions 102, 104, and 106 (Fig. 9 ). These observations suggest that phosphorylated serines at 118 and 167 are required for the regulatory effects of rSTRN3g.
Discussion
In this report, we describe an agonist-dependent association of ERa and rSTRN3g, a protein that recruits the protein phosphatase PP2A, thereby leading to receptor dephosphorylation and reduced transcriptional activity. Nuclear receptor activity depends not only on ligand binding but also on phosphorylation events that occur through intracellular signaling pathways. The mitogen-activated protein kinases (MAPK), ERK-1, and ERK-2 phosphorylate ERa at serine 118 and receptor coactivator proteins at several sites, thereby enhancing transactivational function (Smith 1998 , Font de Mora & Brown 2000 , Kato 2001 , Levin 2003 . TFIIH/CDK7 also phosphorylates ERa at serine 118 (Chen et al. 2000 (Chen et al. , 2002 . RSK1 and -2 kinases activated by MAPK, and AKT phosphorylate ERa at serine 167 (Frodin & Gammeltoft 1999 , Martin et al. 2000 , Clark et al. 2001 , Likhite et al. 2006 . Recent evidence indicates that all of the six identified phosphorylation sites on the coactivator protein, SRC-3, are required for its transactivational function (Wu et al. 2004) . Crosstalk between typical growth factor pathways and ERa are highly dependent upon phosphorylation events and the pathways involved are known to impinge on cellular proliferation, apoptosis, and differentiation (Kato 2001 , Migliaccio et al. 2002 , Levin 2003 . It is therefore likely that PPs play a significant role in regulation of the individual pathways and in the crosstalk between them. Our observations suggest that rSTRN3g modulates ERa activity by acting as a B-subunit of PP2A, thereby dephosphorylating key amino acid residues in the receptor protein. Perhaps proteins that associate with ERa, such as SRC-3, are also dephosphorylated through this mechanism.
Others have shown that phosphorylation of S118 and S167 of ERa regulates DNA-binding affinity, coactivatorbinding affinity, and ligand-specific effects (Likhite et al. 2006) . We showed that ERa phosphorylation at serine 118 is decreased in an okadaic acid-dependent manner by experimental expression of rSTRN3g. Using ERa mutants, we found that both S118 and serine S167 are required for the inhibitory effects of rSTRN3g. It is interesting that the activity of the ERaS167A mutant was not reduced by STRN3g because we might expect that the S118 residue within that receptor protein would be dephosphorylated by the addition of rSTRN3g to the cells, and thus the receptor would effectively lack phosphorylation at both sites. This observation suggests that both S118 and S167 are required for the formation of protein complex of ERa, STRN3g, and PP2A(C), a possibility that will require further testing.
PP2A plays a role in the regulation of multiple cellular signaling pathways, including regulation of steroid receptor activity (Sola et al. 1991 , Borras et al. 1994 , Galigniana et al. 1999 , Bhattacharjee et al. 2001 , and aberrant expression of the enzyme may be involved in cancer etiology (Csortos et al. 1996 , Smith 1998 , Schonthal 2001 , Sontag 2001 . PP2A and another protein phosphate PP5, have been previously implicated in regulation of ER action. It has been noted that PP2A activity is higher and PKC activity is lower in ERa-positive breast cancer cell lines compared with K8 M E 2 1 h prior to harvest. Lysate was subjected to immunoprecipitation (IP) with an antibody against polyhistidine (a-His). The precipitate was probed in a western blot with an antibody against PP2A(C) and ERa. A sample of total lysate (T) was included on the western blot for comparison with the immunoprecipitated material.
ERa-negative lines (Gopalakrishna et al. 1999) . Estradiol-induced down-regulation of ERa protein was inhibited by 100 nM okadaic acid, suggesting that a dephosphorylation event via either PP2A or PP1A was required (Borras et al. 1994) . On the other hand, experimental reduction of PP2A activity, through either expression of siRNA specific to the catalytic subunit of PP2A or by the addition of okadaic acid, decreased the stability of ERa mRNA and reduced receptor protein levels (Keen et al. 2005) . Experimental overexpression of PP5 reduced transcriptional activities of both ERa and -b, and the reduced activity of ERa was correlated with a decrease in the phosphorylation state of the serine 118 residue (Ikeda et al. 2004) .
Protein kinases and phosphatases have been shown to regulate other nuclear receptors and their associated proteins as well. Inhibition of protein phosphatases with okadaic acid or stimulation of PKA enhances transactivational activity of androgen receptor (AR) and progesterone receptor (PR; Beck et al. 1992 , Ikonen et al. 1994 . PR transcriptional activity is cell cycle dependent, probably due to phosphorylation/dephosphorylation events (Narayanan et al. 2005) . Phosphorylation of specific residues regulates nuclear translocation of PR (Qiu et al. 2003) . Dissociation from heat shock protein-90 (HSP90) and subsequent nuclear translocation of GR is dependent upon a dephosphorylation event induced by PP2A, PP1A, or PP5 (DeFranco et al. 1991 , Galigniana et al. 1999 , Zuo et al. 1999 , Dean et al. 2001 , Ismaili & Garabedian 2004 . Likewise, the constitutive AR (CAR) ligand, phenobarbital, induces recruitment of PP2A to the CAR-HSP90 complex and the subsequent okadaic acid-sensitive nuclear translocation of the receptor (Yoshinari et al. 2003) . On the other hand, nuclear localization of the two corepressor proteins, N-CoR and SMRT, is dependent upon PP1 activity (Hermanson et al. 2002 , McKenzie et al. 2005 .
Specificity of PP2A(C) action derives from association with a regulatory B-subunit that controls its intracellular localization and/or substrate recognition (Csortos et al. 1996 , Janssens & Goris 2001 , Sontag 2001 . STRN3 behaves as a B-subunit of PP2A, forming a complex with the regulatory subunit, PP2A(A) and the catalytic subunit, PP2A(C) (Moreno et al. 2000) . We found that ERa associates with STRN3g and this association is enhanced by estrogen. Furthermore, our immunoprecipitation data indicate that the formation of STRN3g-PP2A(C) complex is enhanced by estrogenactivated ERa. It may be that the interaction between ERa and STRN3g alters the conformation of STRN3g so that it has a higher affinity for PP2A(C); this would increase the specificity of the interaction. Lu et al. (2003) reported that PP2A(C) exerts its dephosphorylating effect by binding directly to ERa, but this is unlikely to occur without the benefit of B-and A-subunits; since PP2A subunits are ubiquitous throughout the plant and animal kingdoms, the cell lysates used in their experimental systems could have provided the required A-and B-subunits. The observations that STRN3g does not bind to ERb in a ligand-stimulated fashion and does not affect ERb-induced transcription suggests that its B-subunit activity is restricted to ERa.
The present observations suggest a role for a striatin protein in the mechanism through which PP2A is recruited to a nuclear receptor. rSTRN3g belongs to the striatin family of multimodal proteins. Striatins have been identified in a variety of tissues (Landberg & Tan 1994 , Muro et al. 1995 , Castets et al. 1996 ; see also GenBank (lanes 1-3) or with ERa plus rSTRN3g (lanes 4 and 5). The cells were treated with E 2 and/or okadaic acid as indicated. Separate blots were probed for S118 phosphorylated ERa (ERa-P), total ERa, and rSTRN3g. Figure 9 Effect of rSTRN3g on transactivation by ERa phosphomutants. Cos-1 cells were transfected with 2XERE-luciferase and control reporter and ERa mutants (ER-mut) in which the indicated serine residues were replaced with alanines, and either 0 or 400 ng rSTRN3g. After 24 h the cells were treated with 10 K8 M E 2 or vehicle and cell lysates were prepared 18 h later. rSTRN3g GI nos 10985167, 5853476, 5178755, 4898431) . There are at least three members of the striatin gene family, and in the human they are each located on separate chromosomes as follows: STRN on chromosome 2 (gene ID: 6801); STRN3 on chromosome 14 (gene ID: 29966); and STRN4 on chromosome 19 (gene ID: 97387). Homologs for all three types of striatin have been found in the mouse, rat, and many lower species. Sequence analyses show that all of these proteins contain a putative nuclear localization sequence (Muro et al. 1995) but in some cells, particularly neuronal tissues, they are located entirely in the cytoplasm (Castets et al. 2000 , Moreno et al. 2001 . Striatin proteins are characterized by several WD40 repeat motifs in their carboxy terminal region, and caveolin-and calmodulin-binding sites in their amino terminal region (Castets et al. 2000 , Moreno et al. 2000 . Transactivation and transrepression domains have been identified in STRN3/SG2NA (Zhu et al. 2001) . Sequence analysis of rSTRN3g indicates that it is an isoform of rat STRN3 that arises from a splicing variation, producing a truncated version of the protein. The carboxy terminal truncation yields a protein containing only one out of the six WD40 repeats, the putative transactivation domain and a portion of the transrepression domain. Further investigation is required to determine what portions of the protein are required for ERa binding and repression.
In a recent report, Lu et al. (2004) described an interaction between ERa and STRN. Unlike the interaction between rSTRN3g and ERa, which we describe as occurring through the carboxy half of the receptor protein, the STRN-interacting domain was localized to the N-terminal portion of ERa. It was demonstrated that the ERa-STRN interaction plays a role in the non-genomic effects of estrogen in endothelial cells; furthermore, the evidence suggests that STRN localizes ERa to the cytoplasm. Experimental disruption of the STRN-ERa interaction blocked estradiol induction of MAPK phosphorylation. It was pointed out that disruption of STRN-ERa did not block transactivation of an estrogen-responsive reporter gene; however, interference with this protein-protein interaction actually enhanced the transactivational effect of ERa. This observation suggests that STRN may, like rSTRN3g, act as a repressor protein, dampening the transactivational effects of estrogen.
In summary, rSTRN3g is a novel isoform of the STRN3 gene product that behaves as a B-subunit of PP2A and also interacts with ERa in an agonistdependent manner. Thus, the repressor activity of rSTRN3g derives from its capacity to target PP2A(C) to ERa and perhaps to other proteins associated with the receptor. The intramolecular domains within rSTRN3g that are responsible for these activities are unknown. In addition, evidence presented by others (Lu et al. 2004) suggests that STRN may also exhibit ERa corepressor activity. Whether STRN, STRN3a/b, or STRN4 all represent B-subunits of PP2A and/or nuclear receptor-associated proteins remains to be determined.
